Veloxis Pharmaceuticals
Speciality pharmaceutical company focused on the development and commercialization of Envarsus.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
$1.3b Valuation: $1.3b 227.3x EV/Revenue 74.5x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 30 % | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (27 %) | (13 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (30 %) | (13 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Veloxis Pharmaceuticals operates as a specialty pharmaceutical company with a dedicated focus on the post-transplantation market. The company's origins trace back to its founding in 2002 as a Danish entity, initially listed on the Nasdaq Copenhagen stock exchange. A significant turning point in its history occurred in 2020 when Asahi Kasei, a Japanese chemical company, acquired Veloxis in a transaction valued at approximately $1.3 billion, leading to its delisting and integration into the broader Asahi Kasei Group.
The company's core business revolves around the development and commercialization of therapeutic solutions for transplant patients. Its flagship product is Envarsus XR®, a once-daily tablet formulation of tacrolimus, an immunosuppressant drug. This product is specifically designed to prevent organ rejection in patients who have undergone a kidney transplant. The primary benefit of the Envarsus XR formulation is its extended-release mechanism, which allows for a single daily dose, contrasting with other tacrolimus products that may require twice-daily administration. This simplified dosing regimen is intended to improve patient adherence and convenience.
Veloxis's business model is that of a fully integrated pharmaceutical company, handling everything from clinical development and regulatory approvals to manufacturing and commercial sales. The company generates revenue through the sale of its approved products, primarily Envarsus XR®, in the markets where it has received authorization, including the United States and Europe. Its target clients are transplant centers, physicians, and the patients they serve. By concentrating on the niche market of transplant medicine, Veloxis addresses the specific and ongoing needs of this patient population for effective and manageable immunosuppressive therapies.
Keywords: specialty pharmaceutical, transplant medicine, immunosuppressant, kidney transplant, drug commercialization, Asahi Kasei, Envarsus XR, tacrolimus, organ rejection, patient adherence
